Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors

A DPP-IV, 1. DPP-IV technology, applied in cardiovascular system diseases, medical preparations containing active ingredients, pharmaceutical formulations, etc., can solve problems beyond therapeutic benefits

Inactive Publication Date: 2012-05-09
BRISTOL MYERS SQUIBB CO +1
View PDF76 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, drug use can sometimes be at a level of risk that outweighs therapeutic benefit

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
  • Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
  • Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0028] The present invention relates to a method for preventing all-cause death or reducing the risk of said death in mammals, especially humans, said method comprising administering a therapeutically effective amount of saxagliptin or a drug thereof to a mammal or human in need of said treatment. A salt, a hydrate or a hydrate of a salt and optionally at least one pharmaceutically acceptable carrier are used. A therapeutically effective amount of saxagliptin for preventing or reducing the risk of death from all causes ranges from about 0.5 mg / day to about 400 mg / day. Preferred doses of saxagliptin are 2.5 mg / day, 5 mg / day and 10 mg / day. A therapeutically effective amount of saxagliptin prevents or reduces the risk of all cause mortality in patients with type 2 diabetes mellitus (T2DM) and in non-diabetic animals.

[0029] In another aspect, the present invention relates to the prevention or reduction of all-cause mortality in mammals, particularly humans, with a history of C...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to methods for preventing or reducing the risk of mortality by any means including, but not limited to, cardiovascular events in mammals, particularly humans, comprising administering a dipeptidyl peptidase 4 (DPP-IV) inhibitor to the mammal or human. In addition, the present invention relates to methods for preventing or reducing the risk of non-fatal myocardial infarction and / or non-fatal stroke in mammals, particularly humans, comprising administering a DPP-IV inhibitor to the mammal or human.

Description

technical field [0001] The present invention relates to a method for preventing or reducing the risk of death in mammals, especially humans, from any means including but not limited to cardiovascular events, said method comprising administering to said mammals or humans Dipeptidyl peptidase 4 (dipeptidyl peptidase 4, DPP-IV) inhibitor. The present invention also relates to the prevention or reduction of non-fatal myocardial infarction and / or non-fatal stroke in mammals, especially humans. A method of fatal stroke risk comprising administering to said mammal or human a DPP-IV inhibitor. Background technique [0002] Diabetes mellitus, often shortened to diabetes, is a metabolic disorder syndrome that is usually due to a combination of genetic and environmental factors and results in abnormally high blood sugar levels (hyperglycemia). Blood sugar levels are controlled through a complex interplay of chemicals and hormones in the body, including the hormone insulin, which is p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/40A61K31/4985A61P9/00A61P3/00
CPCA61K31/40A61K31/4985A61P3/00A61P3/06A61P43/00A61P9/00A61P9/10A61P9/12A61P3/10
Inventor R.弗雷德里克J.埃德尔伯格F.菲多雷克
Owner BRISTOL MYERS SQUIBB CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com